In Brief: Scios Nova's Auriculin
Executive Summary
Scios Nova's Auriculin: Preliminary results of a Phase III acute renal failure trial show no difference between patients treated with the atrial natriuretic peptide and those who received placebo in the need for dialysis or mortality, the company reports May 3. Scios said the company and its partner Genentech will further evaluate the data but believe that additional clinical studies will be required for an NDA submission. "We will not meet our objective of filing an application in 1995 for marketing approval," the firm says. Results of the trial will be presented at the International Congress of Nephrology in Madrid, Spain in July. Genentech announced in January that it would be investing up to $100 mil. in Scios Nova's Auriculin R&D...
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth